Brad Thompson, Ph.D. is the co-founder, Chairman, and CEO of Wyvern Pharmaceuticals Inc., a gene therapy company focused on correcting the expression of target genes that are responsible for many chronic diseases and conditions. After receiving his Ph.D. in Microbiology and Immunology in 1981 from the University of Western Ontario, Dr. Thompson went on to spend 23 years as the co-founder, Chairman and CEO of two NASDAQ-listed companies. Seventeen of these years were at an oncology-focused gene therapy company that enrolled over 3,000 patients in Phase 1,2, and 3 clinical trials in 19 countries in Europe and North America. He is a past and present board member of numerous biotechnology and healthcare companies, the author or co- author of more than 60 papers in peer-refereed journals, and the inventor or co-inventor of more than 125 US patents. Dr. Thompson has also recently turned his attention to VCFS and has been speaking frequently with the members of our team of experts in an effort to bring his skills to the management of VCFS.

​

​

​

​

​

​